The concept of foam as a drug carrier for intraperitoneal chemotherapy, feasibility, cytotoxicity and characteristics
Justyna Schubert , Tanja Khosrawipour , Sören Reinhard , Mohamed Arafkas , Alice Martino , Jacek Bania , Marek Pieczka , Alessio Pigazzi , Veria Khosrawipour
AbstractFor decades, intraperitoneal chemotherapy (IPC) was delivered into the abdominal cavity as a liquid solution. This preliminary study aims to evaluate foam as a potential new drug carrier for IPC delivery. Foam-based intraperitoneal chemotherapy (FBIC) was produced with taurolidine, hydrogen peroxide, human serum, potassium iodide and doxorubicin/ oxaliplatin for both ex vivo and in vitro experiments. Analysis of FBIC efcacy included evaluation of cytotoxicity, tissue penetration, foam stability, temperature changes and total foam volume per time evaluation. FBIC showed penetration rates of about 275±87µm and higher cytotoxicity compared to controls and to conventional liquid IPC (p<0.005). The volume of the generated foam was approximately 50-times higher than the initial liquid solution and temporarily stable. Foam core temperature was measured and increased to 47°C after 9min. Foam ingredients (total protein content) were evenly distributed within diferent locations. Our preliminary results are quite encouraging and indicate that FBIC is a feasible approach. However, in order to discuss a possible superior efect over conventional liquid or aerosolized chemo applications, further studies are required to investigate pharmacologic, pharmacodynamic and physical properties of FBIC.
|Journal series||Scientific Reports, ISSN 2045-2322, (N/A 140 pkt)|
|Publication size in sheets||0.5|
|License||Journal (articles only); published final; ; with publication|
|Score||= 140.0, 15-09-2020, ArticleFromJournal|
|Publication indicators||: 2016 = 1.401; : 2018 = 4.011 (2) - 2018=4.525 (5)|
* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.